The United Laboratories International Holdings

The United Laboratories International Holdings is a China-based integrated pharmaceutical company focused on research, development, manufacturing, and commercialization of APIs, finished dosage forms, biopharmaceuticals, and animal health products. The company has a large established commercial business in anti-infectives, diabetes, ophthalmology, cardiovascular, antiviral, dermatology, and other therapeutic categories, while also advancing a biologics pipeline centered on metabolic and chronic diseases. Its more innovative programs include UBT251, a GLP-1/GIP/glucagon triple receptor agonist partnered ex-China with Novo Nordisk, as well as semaglutide, insulin degludec, liraglutide, romosozumab, dupilumab, and a dual-target lipid-lowering candidate. United Lab combines in-house R&D with substantial manufacturing capacity across Hong Kong and mainland China, including insulin, APIs, and finished products, and sells into more than 70 countries and regions.